Neal S Akhave
Overview
Explore the profile of Neal S Akhave including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hamidi S, Dadu R, Zafereo M, Ferrarotto R, Wang J, Maniakas A, et al.
JAMA Oncol
. 2024 Jul;
10(9):1264-1271.
PMID: 38990526
Importance: BRAF/MEK inhibitors revolutionized the treatment of BRAF V600E-variant anaplastic thyroid carcinoma (BRAFv-ATC), offering improved outcomes for patients with this previously incurable disease. Observations: Anaplastic thyroid carcinoma (ATC) accounts for...
2.
Negrao M, Araujo H, Lamberti G, Cooper A, Akhave N, Zhou T, et al.
Cancer Discov
. 2023 Apr;
13(7):1556-1571.
PMID: 37068173
Significance: In this work, we identify co-occurring genomic alterations in KEAP1, SMARCA4, and CDKN2A as independent determinants of poor clinical outcomes with KRASG12Ci monotherapy in advanced NSCLC, and we propose...
3.
Akhave N, Biter A, Hong D
Mol Cancer Ther
. 2022 Oct;
21(11):1645-1651.
PMID: 36282862
The development of selective KRASG12C inhibitors that directly inhibit KRAS, an oncogene historically thought to be "undruggable," represents a watershed moment in oncology and developmental therapeutics. Now, as KRAS-targeted therapy...
4.
Shea L, Akhave N, Sutton L, Compton L, York C, Ramakrishnan S, et al.
J Invest Dermatol
. 2022 Sep;
143(2):232-241.e6.
PMID: 36055401
Cutaneous squamous cell carcinoma (cSCC) has among the highest mutation burdens of all cancers, reflecting its pathogenic association with the mutagenic effects of UV light exposure. Although mutations in cancer-relevant...
5.
Akhave N, Biter A, Hong D
Cancer Discov
. 2021 Apr;
11(6):1345-1352.
PMID: 33820777
mutations are among the most common drivers of human carcinogenesis, and are associated with poor prognosis and an aggressive disease course. With the advent of KRAS inhibitors, the RAS protein...